Extracapsular dissection (ECD) and extended ECD: description of the technique and outcome of treatment.


Journal

The British journal of oral & maxillofacial surgery
ISSN: 1532-1940
Titre abrégé: Br J Oral Maxillofac Surg
Pays: Scotland
ID NLM: 8405235

Informations de publication

Date de publication:
10 2022
Historique:
received: 22 06 2021
revised: 14 10 2021
accepted: 18 10 2021
pubmed: 7 9 2022
medline: 12 10 2022
entrez: 6 9 2022
Statut: ppublish

Résumé

Over the last two decades the senior author has exclusively applied the technique of extracapsular dissection (ECD) and extended ECD to treat discrete, apparently benign parotid tumours. This article describes both techniques and evaluates their application. Simple principles are described to anticipate unexpected malignant tumours and manage lumps safely by wide excision. A retrospective analysis of 97 consecutive patients with discrete, apparently benign parotid lumps is presented. The tumours were classified using the European Salivary Gland Society (ESGS) classification for benign tumours of the parotid gland. The ECD or extended ECD technique was employed irrespective of tumour site or size. A review of patients was carried out after a minimum of six months post surgery by two independent clinicians. The mean (range) hospital stay was one (0-4) night (median 1). Complications were both modest and transient. The temporary facial nerve injury rate was 5/97 (6%). Other complications included haematoma (n=2), sialocele (n=2), and first-bite syndrome (n=2). Independent review post surgery demonstrated a mean Sunnybrook facial grading system score of 98/100 and a mean Stony Brook scar assessment score of 4.5/5. In this series 5/97 (5%) of discreet mobile lumps concealed a low-grade salivary cancer. Experience with the application of ECD in conjunction with its extended form in 97 consecutive patients with discrete parotid lumps is described. The technique is amenable to all parotid lumps, is not restricted by site or size, and has shown minimal morbidity. The risk of recurrent disease could not be addressed.

Identifiants

pubmed: 36068103
pii: S0266-4356(21)00435-6
doi: 10.1016/j.bjoms.2021.10.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1062-1067

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Auteurs

Soudeh Chegini (S)

University College Hospitals London, Specialist Surgery, Head and Neck Surgery, 250 Euston Rd, London NW1 2BU, United Kingdom.

Isabel Sassoon (I)

Brunel University London, Kingston Lane, Uxbridge, Middlesex UB8 3PH, United Kingdom.

Mark McGurk (M)

University College Hospitals London, Specialist Surgery, Head and Neck Surgery, 250 Euston Rd, London NW1 2BU, United Kingdom. Electronic address: Mcgurk.mark@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH